This week, in a big win for consumers, a district court took action to block the proposed merger between health insurance giants Anthem and Cigna. This decision follows a ruling last month that blocked the proposed merger of two more of the nation’s biggest for-profit health insurers, Aetna and Humana. These decisions come after months of work by U.S. PIRG and a broad coalition of consumer and health care groups, urging close scrutiny of the mergers from state and federal regulators and raising questions and concerns about the potential impact of the mergers.
Many consumers who buy their own health insurance face a big decision right now. Should you renew your existing plan, or switch to a new one?
It’s an especially important decision for consumers whose insurance company is giving them the option to stay in a “pre-ACA plan” – one that falls below minimum standards under the Affordable Care Act – for another year.
Here are our tips for consumers, and a checklist to help you make the decision that’s right for you:
Having the facts can make all the difference when it comes to health insurance. To make the most of new choices, protections and financial help, you need good information. This guide can help you find quality coverage that won’t break the bank.
We are two months away from New Jersey’s health insurance exchange going live, and thousands of New Jerseyans who stand to benefit won't even know about their new, affordable options unless the Governor releases the funds for outreach and education.
New Jerseyans with cancer, heart disease, epilepsy and other conditions have been forced to pay an average of 10 times more than necessary for at least 20 blockbuster drugs. Brand drug manufacturers have made $98 billion in total sales off the drugs while the generic versions were delayed.
Too often, consumers are forced to shoulder a heavy financial burden, or even go without needed medicine, due to the high cost of brand-name drugs. Our research indicates that one significant cause is the practice called “pay for delay,” which inflates the drug prices paid by tens of millions of Americans.
The contaminated drug that caused last fall’s fungal meningitis outbreak, killing 55 people nation-wide and sickening 51 New Jerseyans, is just the tip of the iceberg of an industry-wide problem, according to a new report released today by NJPIRG.
The fungal meningitis outbreak caused by contaminated steroid injections that killed 55 people to date and sickened more than 740 is one of the worst public health disasters the nation has seen in recent history. The tainted injections came from a drug manufacturer doing business as a “compounding pharmacy,” a classification which allowed them to evade the system of safety rules, inspections, and oversight that keep our drug supply safe.